Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects (Q46177871)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16305071

retrieved

20 December 2017

reference URL

http://europepmc.org/abstract/MED/16305071

title

Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16305071

retrieved

20 December 2017

reference URL

http://europepmc.org/abstract/MED/16305071

main subject

inflammation

0 references

(RS)-rosiglitazone

1 reference

based on heuristic

inferred from title

insulin resistance

1 reference

based on heuristic

inferred from title

author

Gerald Reaven

series ordinal

5

object named as

Gerald M Reaven

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16305071

retrieved

20 December 2017

author name string

James W Chu

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16305071

retrieved

20 December 2017

reference URL

http://europepmc.org/abstract/MED/16305071

Fahim Abbasi

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16305071

retrieved

20 December 2017

reference URL

http://europepmc.org/abstract/MED/16305071

Cynthia Lamendola

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16305071

retrieved

20 December 2017

reference URL

http://europepmc.org/abstract/MED/16305071

Tracey McLaughlin

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16305071

retrieved

20 December 2017

reference URL

http://europepmc.org/abstract/MED/16305071

Philip S Tsao

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16305071

retrieved

20 December 2017

reference URL

http://europepmc.org/abstract/MED/16305071

language of work or name

English

0 references

publication date

1 February 2005

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16305071

retrieved

20 December 2017

reference URL

http://europepmc.org/abstract/MED/16305071

published in

Diabetes and Vascular Disease Research

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16305071

retrieved

20 December 2017

reference URL

http://europepmc.org/abstract/MED/16305071

volume

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16305071

retrieved

20 December 2017

reference URL

http://europepmc.org/abstract/MED/16305071

issue

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16305071

retrieved

20 December 2017

reference URL

http://europepmc.org/abstract/MED/16305071

page(s)

37-41

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16305071

retrieved

20 December 2017

reference URL

http://europepmc.org/abstract/MED/16305071

cites work

Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.3132%2FDVDR.2005.004

retrieved

21 January 2018

Multiple lipoprotein abnormalities associated with insulin resistance in healthy volunteers are identified by the vertical auto profile-II methodology

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.3132%2FDVDR.2005.004

retrieved

21 January 2018

Comparison of plasminogen activator inhibitor-1 concentration in insulin-resistant versus insulin-sensitive healthy women

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.3132%2FDVDR.2005.004

retrieved

21 January 2018

Differentiation between obesity and insulin resistance in the association with C-reactive protein

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.3132%2FDVDR.2005.004

retrieved

21 January 2018

Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.3132%2FDVDR.2005.004

retrieved

21 January 2018

Metabolic and additional vascular effects of thiazolidinediones.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.3132%2FDVDR.2005.004

retrieved

21 January 2018

Nonhypoglycemic effects of thiazolidinediones

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.3132%2FDVDR.2005.004

retrieved

21 January 2018

A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.3132%2FDVDR.2005.004

retrieved

21 January 2018

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.3132%2FDVDR.2005.004

retrieved

21 January 2018

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.3132%2FDVDR.2005.004

retrieved

21 January 2018

Roles of peroxisome proliferator-activated receptor gamma in lipid homeostasis and inflammatory responses of macrophages

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.3132%2FDVDR.2005.004

retrieved

21 January 2018

Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.3132%2FDVDR.2005.004

retrieved

21 January 2018

Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: reversal with rosiglitazone.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.3132%2FDVDR.2005.004

retrieved

21 January 2018

Vascular smooth muscle cell activation by C-reactive protein

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.3132%2FDVDR.2005.004

retrieved

21 January 2018

Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.3132%2FDVDR.2005.004

retrieved

21 January 2018

Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.3132%2FDVDR.2005.004

retrieved

21 January 2018

The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.3132%2FDVDR.2005.004

retrieved

21 January 2018

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.3132%2FDVDR.2005.004

retrieved

21 January 2018

Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.3132%2FDVDR.2005.004

retrieved

21 January 2018

Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.3132%2FDVDR.2005.004

retrieved

21 January 2018

Identifiers

DOI

10.3132/DVDR.2005.004

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16305071

retrieved

20 December 2017

reference URL

http://europepmc.org/abstract/MED/16305071

PubMed publication ID

16305071

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16305071

retrieved

20 December 2017

reference URL

http://europepmc.org/abstract/MED/16305071

ResearchGate publication ID

7463890

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46177871&oldid=2098477298"